The global flow cytometry market is projected to reach USD 7.0 billion by 2028 from an estimated USD 4.7 billion in 2023, at a CAGR of 8.3% during the forecast period. Increased adoption of flow cytometry in clinical applications in emerging nations coupled with rising emphasis on stem cell research activities are some of the major factors likely to upsurge the market growth. However, the high cost of instruments is one of the major factors likely to negatively impact the growth of the market.
The flow cytometry market is competitive & consolidated in nature, and various market players operating in the market are adopting strategies to sustain market competition. Prominent players in the global flow cytometry market are BD (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), and others.
To know about the assumptions considered for the study download the pdf brochure
BD is the leading player in the flow cytometry market. The company offers a significant number of products and strongly emphasizes product launches with technological advancements. The company operates through three business segments BD Medical, BD Life Sciences, and BD Interventional. The company’s emphasis on innovative and user-friendly innovations for flow cytometry has helped retain its dominant position in the flow cytometry market. Various factors, such as the launch of technologically advanced instruments and a strong geographical presence, are attributable to the supremacy of BD in the flow cytometry market. In June 2023, BD launched BD FACSDuet Premium Sample Preparation System, which is a new automated instrument that prepares samples for clinical diagnostics using flow cytometry.
Danaher Corporation (US)
Danaher Corporation is one of the leading players in the flow cytometry market. Danaher (US) acquired Beckman Coulter, Inc, in June 2011. Danaher manufactures, designs, and markets medical, industrial, and commercial products & services across the globe. The company mainly strategizes its growth through collaborations, acquisitions, and product & service launches. Beckman Coulter significantly impacts Danaher’s revenue through ground-breaking research, technological advancements in products, geographical expansion, and the launch of pioneering flow cytometry products. The company has had a noteworthy number of product launches and acquisitions in the flow cytometry market in the past few years. This implies the company’s focused strategy to arise as a leader in the market in the coming years.
Thermo Fisher Scientific, Inc. (US)
Thermo Fisher Scientific, Inc. (US) is one of the leading players in the flow cytometry market in 2022. The company’s leading position is attributable to its diversified product & service portfolio, strong geographic presence, and adoption of organic and inorganic growth strategies. The company has adopted different growth strategies, such as deals that include agreements, acquisitions, and expansions, to maintain its leading position in the flow cytometry market. Thermo Fisher Scientific has concentrated its focus on the implementation of advanced technologies. For example, in February 2021, the company acquired cell sorting technology assets from Propel Labs.
Flow Cytometry Market by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End-user, Region - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE